NASDAQ : NVCR
NovoCure Limited — Key statistics
Healthcare · Medical Devices · Switzerland
Last price 13.11 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.53B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.54B |
| Enterprise Value | 1.31B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 116.92M |
| Shares Outstanding | 116.92M |
| Shares Change (YoY) | +3.87% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 8.65% |
| Owned by Institutions (%) | 82.34% |
| Float | 96.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.12 |
| Forward PS | 2.00 |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.49 |
| Quick Ratio | 2.30 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -35.18% |
| Return on Assets (ROA) | -6.79% |
| Return on Invested Capital (ROIC) | -95.37% |
| Return on Capital Employed (ROCE) | -21.33% |
| Weighted Average Cost of Capital (WACC) | 10.12% |
| Revenue Per Employee | $451,955 |
| Profits Per Employee | -$75,844 |
| Employee Count | 1,605 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 4.14 |
Taxes
| Measure | Value |
|---|
| Income Tax | -8.81M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -2.45% |
| 50-Day Moving Average | 15.79 |
| 200-Day Moving Average | 14.82 |
| Relative Strength Index (RSI) | 34.05 |
| Average Volume (20 Days) | 1,978,804 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.82M |
| Short Previous Month | 11.16M |
| Short % of Shares Out | 10.97% |
| Short % of Float | 13.23% |
| Short Ratio (days to cover) | 9.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 725.39M |
| Gross Profit | 560.38M |
| Operating Income | -119.04M |
| Pretax Income | -130.54M |
| Net Income | -121.73M |
| EBITDA | -103.49M |
| EBIT | -119.04M |
| Loss Per Share | -$1.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 463.48M |
| Total Debt | 231.55M |
| Net Cash | 231.93M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 350.61M |
| Book Value Per Share | 3.12 |
| Working Capital | 402.86M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -722,000 |
| Capital Expenditures | -23.89M |
| Depreciation & Amortization | 15.55M |
| Net Borrowing | -560.95M |
| Free Cash Flow | -24.61M |
| FCF Per Share | -$0.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.25% |
| Operating Margin | -16.41% |
| Pretax Margin | -18.00% |
| Profit Margin | -16.78% |
| EBITDA Margin | -14.27% |
| EBIT Margin | -16.41% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.87% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.06% |
| FCF Yield | -1.60% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $26.43 |
| Price Target Difference | 100.99% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 12.57% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.69 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |